Levodopa

CHEMBL1009 Phase 4 Одобрено Small molecule

Half-Life

1.5 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

197.2 g/mol

LogP

-2.7

Phase

4

A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

Молекулярная масса

197,1880 g/mol

LogP

-2,70

TPSA

104,00 Å²

Правило пяти Липинского

Соответствует

Терапевтические области

Age-Related Macular Degeneration Pain Management Asthma Alzheimer's Disease Parkinson's Disease Schizophrenia Generalized Anxiety Disorder Stroke Type 2 Diabetes Major Depressive Disorder Chronic Pain

Классы препаратов

N — N - Nervous System

Механизм действия

Metabolic precursor of dopamine that crosses the BBB.

Pharmacokinetics (PK)

Half-Life 1.5 hours

Pharmacodynamics (PD)

Механизм

Metabolic precursor of dopamine that crosses the BBB.

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O

InChI

InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

Molecular Formula

C9H11NO4

HBD / HBA

4 / 5

Вращаемые Связи

3

Тяжёлые Атомы

14

DRD2 (Dopamine D2 Receptor) Agonist

Primary Target

ABCB1 (P-glycoprotein) Substrate

Major Levodopa + Quetiapine

Quetiapine, a D2 receptor antagonist, pharmacodynamically opposes levodopa's dopaminergic effect, worsening Parkinson's disease motor symptoms.

Major Levodopa + Aripiprazole

Aripiprazole acts as a partial D2 agonist/antagonist and can oppose levodopa's dopaminergic therapy, worsening Parkinson's disease symptoms.

Moderate Levodopa + Carbamazepine

Carbamazepine may reduce levodopa efficacy through enzyme induction and pharmacodynamic antagonism, potentially worsening Parkinson's disease control.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

Metabolic precursor of dopamine that crosses the BBB.

Key pharmacokinetic parameters for Levodopa: Half-life: 1.5 hours.

Yes, Levodopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

ADME Journey →

Related Drugs

Same Drug Class

Acetaminophen Small molecule Aspirin Small molecule Sertraline Small molecule Escitalopram Small molecule

Same Target

Quetiapine Small molecule Aripiprazole Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1009. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6047. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Ищете информацию, доступную для пациентов?

Levodopa на PillFYI

Структура

Краткие Данные

Class: N - Nervous System
Формула: C9H11NO4
Синонимы: 11

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Levodopa

Терапевтические области

Классы препаратов

Механизм действия

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

Cite this structure

Embed this structure

No side effects recorded

Часто задаваемые вопросы

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget